Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiora Pharmaceuticals (KPRX) Other Non Operating Income (2021 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Other Non Operating Income for 6 consecutive years, with -$23708.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non Operating Income rose 60.44% year-over-year to -$23708.0, compared with a TTM value of -$36720.0 through Sep 2025, up 77.37%, and an annual FY2024 reading of $26073.0, down 9.6% over the prior year.
  • Other Non Operating Income was -$23708.0 for Q3 2025 at Kiora Pharmaceuticals, up from -$93556.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $105715.0 in Q3 2023 and bottomed at -$278190.0 in Q4 2021.
  • Average Other Non Operating Income over 5 years is -$29654.7, with a median of -$17557.0 recorded in 2024.
  • The sharpest move saw Other Non Operating Income soared 11182.28% in 2023, then crashed 396.03% in 2025.
  • Year by year, Other Non Operating Income stood at -$278190.0 in 2021, then skyrocketed by 100.34% to $937.0 in 2022, then plummeted by 9869.48% to -$91540.0 in 2023, then skyrocketed by 205.74% to $96797.0 in 2024, then crashed by 124.49% to -$23708.0 in 2025.
  • Business Quant data shows Other Non Operating Income for KPRX at -$23708.0 in Q3 2025, -$93556.0 in Q2 2025, and -$16253.0 in Q1 2025.